By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

Findings suggest this method could provide data about tumors sooner than MRIs alone.

The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

In a clinical trial, adding interferon treatment with a bone marrow transplant bolstered outcomes for patients with advanced, high-risk leukemia.

The effort by the Michigan Radiation Oncology Quality Consortium reduced unnecessary medical procedures, and saved the time and resources of patients and families.